HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Proprotein Convertases (Pro-Opiomelanocortin Converting Enzyme)

Subscribe to New Research on Proprotein Convertases

Proteolytic enzymes that are involved in the conversion of protein precursors such as peptide prohormones into PEPTIDE HORMONES. Some are ENDOPEPTIDASES, some are EXOPEPTIDASES.

Also Known As:

Pro-Opiomelanocortin Converting Enzyme; POMC Convertase; POMC Enzyme; POMC-Converting Enzyme; Pro-Opiocortin Converting Enzyme; Pro-Opiocortin Converting Protease; Prohormone Convertase; Proopiomelanocortin Convertase; Subtilisin-Like Proprotein Convertases; Convertase, POMC; Convertase, Prohormone; Convertase, Proopiomelanocortin; Convertase, Proprotein; Convertases, Prohormone; Convertases, Proprotein; Convertases, Subtilisin-Like Proprotein; Converting Enzyme, Pro-Opiocortin; Converting Enzyme, Pro-Opiomelanocortin; Converting Protease, Pro-Opiocortin; POMC Converting Enzyme; Pro Opiocortin Converting Enzyme; Pro Opiocortin Converting Protease; Pro Opiomelanocortin Converting Enzyme; Proprotein Convertases, Subtilisin-Like; Subtilisin Like Proprotein Convertases; Prohormone Convertases; Proprotein Convertase

Networked: 360 relevant articles (12 outcomes, 26 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Seidah, Nabil G: 30 articles (01/2015 - 06/2002)
2.	Day, Robert: 12 articles (02/2015 - 07/2007)
3.	Prat, Annik: 11 articles (01/2015 - 08/2004)
4.	Bassi, Daniel E: 10 articles (10/2015 - 04/2002)
5.	Khatib, Abdel-Majid: 9 articles (01/2015 - 06/2002)
6.	Varret, Mathilde: 9 articles (09/2014 - 08/2004)
7.	Lindberg, Iris: 8 articles (07/2015 - 02/2010)
8.	Boileau, Catherine: 8 articles (09/2014 - 08/2004)
9.	Abifadel, Marianne: 8 articles (09/2014 - 08/2004)
10.	Scamuffa, Nathalie: 7 articles (06/2014 - 09/2007)

Related Diseases

1.	Hypercholesterolemia 01/01/2015 - "Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors have emerged as a novel treatment option in patients with hypercholesterolemia. " 06/01/2015 - "Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials." 05/01/2015 - "Results of bococizumab, a monoclonal antibody against proprotein convertase subtilisin/kexin type 9, from a randomized, placebo-controlled, dose-ranging study in statin-treated subjects with hypercholesterolemia." 09/01/2014 - "This analysis evaluated the effect of a monoclonal antibody to proprotein convertase subtilisin/kexin 9, alirocumab 150 mg every 2 weeks (Q2W), on Lp(a) levels in pooled data from 3 double-blind, randomized, placebo-controlled, phase 2 studies of 8 or 12 weeks' duration conducted in patients with hypercholesterolemia on background lipid-lowering therapy (NCT01266876, NCT01288469, and NCT01288443). " 03/01/2015 - "Alirocumab, a fully human monoclonal antibody to proprotein convertase subtilisin/kexin type 9, is in Phase III development for the treatment of hypercholesterolemia. "
2.	Cardiovascular Diseases (Cardiovascular Disease) 01/25/2008 - "The proprotein convertase PCSK9 gene is the third locus implicated in familial hypercholesterolemia, emphasizing its role in cardiovascular diseases. " 10/27/2015 - "Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition: A New Therapeutic Mechanism for Reducing Cardiovascular Disease Risk." 09/15/2015 - "Over the last decade, inhibition of Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) has emerged as a promising target to reduce residual cardiovascular disease risk. " 04/01/2015 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as an attractive therapeutic target for cardiovascular disease. " 01/01/2013 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a novel biomarker of LDL clearance and a therapeutic target of cardiovascular disease. "
3.	Hyperlipidemias (Hyperlipidemia) 11/01/2015 - "Bococizumab is a humanized monoclonal IgG2Δa antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) for the treatment of hyperlipidemia. " 06/01/2011 - "The role of proprotein convertase subtilisin/kexin type 9 in hyperlipidemia: focus on therapeutic implications." 01/01/2015 - "Proprotein convertase subtilisin/kexin type 9 (encoded by PCSK9) plays a well-known role in the regulation of low-density lipoprotein (LDL) receptors, and an inhibitor of this enzyme is a promising new therapeutic for hyperlipidemia. " 04/01/2015 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9), a newly-identified member that plays an essential role in cholesterol homeostasis and holds decent promise for hyperlipidemia and coronary artery disease (CAD) treatment. " 02/01/2015 - "Inhibition of proprotein convertase subtilisin/kexin type 9: a novel mechanism of berberine and 8-hydroxy dihydroberberine against hyperlipidemia."
4.	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 08/01/2004 - "How does mutant proprotein convertase neural apoptosis-regulated convertase 1 induce autosomal dominant hypercholesterolemia?" 08/01/2004 - "Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia." 01/25/2008 - "The proprotein convertase PCSK9 gene is the third locus implicated in familial hypercholesterolemia, emphasizing its role in cardiovascular diseases. " 05/01/2015 - "In this article, we will briefly review familial hypercholesterolemia and the role of proprotein convertase subtilisin/kexin 9 inhibitors in this condition. " 05/01/2015 - "The promise of proprotein convertase subtilisin/kexin 9 inhibitors for the treatment of familial hypercholesterolemia."
5.	Dyslipidemias (Dyslipidemia) 07/01/2007 - "The proprotein convertases are potential targets in the treatment of dyslipidemia." 06/01/2015 - "Potential blockbuster therapies, such as proprotein convertase subtilisin/kexin type 9 inhibitors, are expected to revolutionize dyslipidemia treatment and raise global sales. " 12/01/2013 - "Proprotein convertase subtilisin/kexin type 9 (PCSK9) and LDL lowering in the contemporary management of dyslipidemia." 11/01/2013 - "Current Phase II proprotein convertase subtilisin/kexin 9 inhibitor therapies for dyslipidemia." 03/01/2015 - "Inhibitors of proprotein convertase subtilisin kexin type 9 (PCSK9) represent a new therapeutic category of drugs for the treatment of dyslipidemia and atherosclerotic cardiovascular disease. "

Related Drugs and Biologics

1.	Subtilisin
2.	LDL Receptors (LDL Receptor)
3.	LDL Cholesterol
4.	Cholesterol
5.	Serine Proteases (Serine Protease)
6.	Furin
7.	Lipoproteins (Lipoprotein)
8.	Antibodies
9.	atorvastatin (Lipitor)
10.	Enzymes

Related Therapies and Procedures

1.	Cardiac Resynchronization Therapy
2.	Drug-Eluting Stents
3.	Bariatric Surgery
4.	Implantable Defibrillators (Implantable Cardioverter-Defibrillator)
5.	Pneumonectomy (Lung Volume Reduction)